Cibus, which is developing gene-edited crop traits for the global seed industry, postponed its IPO on Thursday. It had filed to raise $100 million by offering 6.7 million shares at a price range of $14 to $16.
The San Diego, CA-based company was founded in 2001 and booked $3 million in sales for the 12 months ended September 30, 2018. It had planned to list on the Nasdaq under the symbol CBUS. Morgan Stanley, BofA Merrill Lynch and Piper Jaffray were set to be the joint bookrunners on the deal.
